Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02153437 · ClinicalTrials.gov registry record · Phase 1
Study of the Effects of BMS-919373 on the Electrical Activity of the Heart Using Pacemakers
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Terminated
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT02153437 is a Phase 1 study that was terminated before completion, run by Bristol-Myers Squibb. The registered enrollment target is 7 participants.
The verdict
NCT02153437, a Phase 1 study, was terminated before completion, sponsored by Bristol-Myers Squibb.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
To determine the effect of our compound (BMS-919373) on electrical activity of the heart using pacemakers.
Interventions
- DRUG Sotalol
- DRUG BMS-919373
- DRUG Placebo for BMS-919373
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2014-10-30 |
| Est. Completion | 2016-10-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02153437
The ClinicalTrials.gov registry entry for NCT02153437 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Sotalol is the first listed.
NCT02153437 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02153437 about?
NCT02153437 is a clinical study titled "Study of the Effects of BMS-919373 on the Electrical Activity of the Heart Using Pacemakers". To determine the effect of our compound (BMS-919373) on electrical activity of the heart using pacemakers.
What is the current status of trial NCT02153437?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2014-10-30. Estimated completion is 2016-10-20.
What interventions are being tested in trial NCT02153437?
The interventions under investigation include: Sotalol (DRUG), BMS-919373 (DRUG), Placebo for BMS-919373 (DRUG).
Who is sponsoring clinical trial NCT02153437?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.